Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1322 of 5804
-
New epilepsy drug tested as standalone treatment
Disease control OngoingCenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, the…
Phase: PHASE4 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New blood pressure combo pill aims to beat standard treatment
Disease control Recruiting nowPhase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Phase: PHASE3 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Balloon 'Postconditioning' may shield brain after stroke
Disease control CompletedThis study aims to determine the safety and optimal dose of rapid local ischemic postconditioning in acute ischemic stroke(AIS) patients received successful thrombectomy reperfusion. In this trial, investigators will halt antegrade cerebral blood flow temporarily by the way of ba…
Phase: NA • Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug could soothe unbearable itch in rare liver conditions
Symptom relief OngoingThe purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment op…
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Magnetic bypass: a new tool to fight obesity and diabetes without cutting?
Disease control CompletedThe objective of the MagDI Chile Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (…
Phase: NA • Sponsor: GT Metabolic Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Hope for rare fat disorder: new drug shows promise in Long-Term trial
Disease control Recruiting nowThis Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
5-Minute MRI could solve brain tumor mystery after radiation
Diagnosis Recruiting nowThe purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Poop pills from different donors: a new hope for ulcerative colitis?
Disease control CompletedInflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects over 2 million people worldwide . Although biological therapies have significantly improved the treatment outcomes for UC, nearly two-thirds of patients experience diminishing dr…
Phase: NA • Sponsor: First Affiliated Hospital of Kunming Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Boron therapy shows promise for tough brain tumors
Disease control CompletedThis Phase I/II study, titled 'A Study to Evaluate the Safety and Efficacy of Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA as a Boron Carrier in Recurrent Meningioma', aims to assess the efficacy of B10 L-BPA with BNCT in patients with recurrent meningioma. The primary ob…
Phase: PHASE1, PHASE2 • Sponsor: Heron Neutron Medical Corp. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New inhaler could ease tooth pain in minutes
Symptom relief CompletedWith a chronic shortage of dentists in some regions, and an increase in life expectancy and living conditions, the number of patients admitted to oral health emergencies is on the rise. Pain is the main reason for consultation, and is particularly exacerbated in the orofacial sph…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New spinal injection aims to tame Huntington's
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Phase: PHASE1 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Wearable patch and phone app could spot dangerous fevers before they spike in cancer therapy
Knowledge-focused CompletedThe purpose of this study is to evaluate two vital sign monitoring devices, TempTraq and VitalTraq, in patients with hematologic malignancies undergoing therapy with Chimeric antigen receptor T-cell therapy (CAR-T) or Bispecific T-cell engagers (BiTE) products. TempTraq is an axi…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Poop pills vs. pancreatitis: can gut transplants stop deadly infections?
Disease control Recruiting nowThis study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.
Phase: NA • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:29 UTC
-
New pill shows promise for kidney disease patients
Disease control CompletedEvaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedApproximately 10% of patient develop AML after chemotherapy or radiation for unrelated disease (t-AML) and 20% have AML with an antecedent hematologic disorder (AML-MRC). CPX-351 (Vyxeos), a liposomal formulation of a fixed molar ratio (1:5) daunorubicin and cytarabine, has been …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a diabetes drug boost weight loss after teen bariatric surgery?
Disease control Recruiting nowThe study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn mo…
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Smart test could tailor breast cancer treatment and boost quality of life
Diagnosis Recruiting nowThe primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer. Patients randomized to arm A will receive adjuvant treatment by physician´s choice, …
Phase: NA • Sponsor: Fundacio Clinic Barcelona • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New hope for tough leukemia: first human trial of KK2845 begins
Disease control Recruiting nowThis is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies, in Part 1, the tolerability of KK2845 will be eva…
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill RAP-219 tested for stubborn seizures
Disease control CompletedThis is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Phase: PHASE2 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New antibody drug aims to tame ulcerative colitis
Disease control Recruiting nowThe Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
Phase: PHASE1, PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC